Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the Lilly Medical website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical

  1. Medical Information Right
  2. Diabetes Right
  3. Mounjaro (tirzepatide) injection Right
  4. Why did Lilly measure the proportion of participants achieving HbA1c levels of <7%, ≤6.5%, and <5.7%?
Search Mounjaro (tirzepatide) injection (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Mounjaro ® (tirzepatide) injection

2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

Why did Lilly measure the proportion of participants achieving HbA1c levels of <7%, ≤6.5%, and <5.7%?

The HbA1c levels were chosen based on select guidelines and definitions of glycemic classification.

US_cFAQ_TZP301_SURPASS_HBA1C_TARGETS
US_cFAQ_TZP301_SURPASS_HBA1C_TARGETS
en-US

SURPASS Study HbA1c Values

A glycated hemoglobin (HbA1c) of <7% is the recommended target for most nonpregnant adults with type 2 diabetes (T2D) according to the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD).1,2

An HbA1c of ≤6.5% is the recommended target for most nonpregnant adults with T2D if this target can be achieved safely according to the American Association of Clinical Endocrinology (AACE) clinical practice guideline.3

An HbA1c <5.7% is considered a normal HbA1c level, or the level seen in people without T2D.4

References

1American Diabetes Association. Standards of care in diabetes—2023. Diabetes Care. 2023;46(suppl 1):S1-S292. https://diabetesjournals.org/care/issue/46/Supplement_1

2Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753-2786. https://doi.org/10.2337/dci22-0034

3Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan—2022. Endocr Pract. 2022;28(10):923-1049. https://doi.org/10.1016/j.eprac.2022.08.002

4Understanding A1C. American Diabetes Association. Accessed April 25, 2023. https://www.diabetes.org/a1c

Date of Last Review: April 25, 2023

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Consumer Health Privacy Notice
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.44 4/2025 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2025. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    California Consumer Privacy Act (CCPA) Opt-Out Icon Your Privacy Choices
    Cookie Settings
    facebook twitter linkedin
    visit www.phactmi.org
    Lilly